Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anaemia

Trial Profile

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anaemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Epoetin alfa
  • Indications Anaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms ChOPIN
  • Most Recent Events

    • 10 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 28 Feb 2018.
    • 24 Oct 2017 Planned number of patients changed from 15000 to 252.
    • 22 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top